Stereotaxis (STXS) Cash from Financing Activities (2010 - 2026)
Stereotaxis (STXS) reported Cash from Financing Activities of $4.7 million for Q1 2026, up 14637.5% year-over-year from N/an in Q1 2025, and down 32.18% quarter-over-quarter from $7.0 million in Q4 2025.
Stereotaxis (STXS) Cash from Financing Activities (2010 - 2026) Analysis & Trends
Stereotaxis (STXS) has 17 years of Cash from Financing Activities data on file, last reported at $4.7 million in Q1 2026.
- Cash from Financing Activities for Q1 2026 came in at $4.7 million, up 14637.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $19.4 million (up 6404.01% YoY), and the FY2025 annual result was $14.8 million, up 4870.71% from the prior year.
- Cash from Financing Activities slipped to $4.7 million in Q1 2026 per STXS's latest filing, from $7.0 million in the prior quarter.
- Over five years, Cash from Financing Activities peaked at $7.7 million in Q3 2025 and troughed at -$26000.0 in Q2 2023.
- A 5-year average of $1.2 million and a median of $54000.0 in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2026: Cash from Financing Activities slumped 145.61% in 2023, then surged 14637.5% in 2026.
- A 5-year view of Cash from Financing Activities shows it stood at $61000.0 in 2022, then tumbled by 57.38% to $26000.0 in 2023, then soared by 511.54% to $159000.0 in 2024, then jumped by 4273.58% to $7.0 million in 2025, then tumbled by 32.18% to $4.7 million in 2026.
- Business Quant data shows STXS's Cash from Financing Activities at $4.7 million in Q1 2026, $7.0 million in Q4 2025, and $7.7 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing (Qtr) |
|---|---|---|---|---|---|
| 1 | Intuitive Surgical | 148.09 Bn | 143.69 Bn | 1.83 Bn | -1.35 Bn |
| 2 | Becton Dickinson | 41.00 Bn | 39.99 Bn | 2.15 Bn | -414.00 Mn |
| 3 | Medline | 30.38 Bn | 36.22 Bn | 1.84 Bn | -13.00 Mn |
| 4 | Resmed | 28.22 Bn | 26.56 Bn | 890.98 Mn | -255.24 Mn |
| 5 | West Pharmaceutical Services | 23.72 Bn | 23.19 Bn | 296.40 Mn | -308.70 Mn |
| 6 | Solventum | 13.33 Bn | 13.33 Bn | 1.10 Bn | -50.00 Mn |
| 7 | Cooper Companies | 13.12 Bn | 12.99 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Align Technology | 12.86 Bn | 11.80 Bn | 736.59 Mn | -48.13 Mn |
| 9 | Baxter International | 10.51 Bn | 8.47 Bn | 891.00 Mn | -11.00 Mn |
| 10 | Stereotaxis | 180.48 Mn | 165.86 Mn | 3.79 Mn | 4.72 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.72 Mn |
| Mar 31, 2026 | 4.72 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Dec 31, 2025 | 6.95 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Sep 30, 2025 | 7.74 Mn |
| Jun 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 34,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Mar 31, 2025 | 32,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Dec 31, 2024 | 159,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Sep 30, 2024 | 80,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Jun 30, 2024 | 28,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Mar 31, 2024 | 30,000.00 |
| Dec 31, 2023 | 26,000.00 |
| Dec 31, 2023 | 26,000.00 |